Doxorubicin News and Research

RSS

Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.

In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.

Researchers discover a protein linked with the onset of anthracycline-associated cardiac toxicity

Anthracyclines are a class of chemotherapies effective in treating many forms of cancer, including leukemias, lymphomas and breast cancer.

27 Dec 2022

IU researchers uncover new ways to prevent serious side effects for breast cancer patients

Researchers at Indiana University School of Medicine are learning more about ways to prevent serious side effects from chemotherapy used to treat breast cancer patients.

20 Dec 2022

Scientists map neural pathways that lead to vomiting after eating contaminated food

A new study describes a system by which gut-brain pathways coordinate with brain circuits to initiate nausea and vomiting.

6 Nov 2022

Investigating the role of the gut-to-brain axis in defensive responses

In a new study, researchers investigated the function of the gut-to-brain axis in defensive responses induced by toxins.

3 Nov 2022

Molecular drug transporters could improve treatment of cancers and other diseases

A team of Canadian researchers from Université de Montréal has designed and validated a new class of drug transporters made of DNA that are 20,000 times smaller than a human hair and that could improve how cancers and other diseases are treated.

2 Nov 2022

Penn State researchers lay the foundation for precision fabrication of tumor models

Researchers at Penn State have successfully 3D bioprinted breast cancer tumors and treated them in a breakthrough study to better understand the disease that is one of the leading causes of mortality worldwide.

18 Oct 2022

Novel drug target for triple-negative breast cancer discovered

Research led by Dr. Suresh Alahari, Professor of Biochemistry at LSU Health New Orleans' Schools of Medicine and Graduate Studies, reports a combination of a novel small inhibitory molecule and an FDA-approved chemotherapy drug suppresses the growth of triple-negative breast cancer cells synergistically.

17 Oct 2022

Did the diagnosis and management of Hodgkin lymphoma differ during the SARS-CoV-2 pandemic?

In a new study, researchers evaluated the impact of the SARS-CoV-2 pandemic on the diagnosis and treatment of classical Hodgkin lymphoma (cHL) patients in Istanbul, Turkey.

17 Oct 2022

Exploring remdesivir resistance in COVID-19-infected transplant recipients

In a new study, researchers assessed the remdesivir resistance developed in coronavirus disease 2019 (COVID-19)-infected transplant recipients.

29 Sep 2022

Study estimates the cost-effectiveness of therapeutic alternatives

Giving standard chemotherapy drugs in a specific sequence for some types of metastatic breast cancer can help reduce overall costs and improve the value of care while preserving quality of life, according to a study led by UNC Lineberger Comprehensive Cancer Center and UNC Gillings School of Global Public Health researchers.

14 Sep 2022

New advice aims to reduce the cardiac side effects of cancer treatment

The first European Society of Cardiology Guideline on cardio-oncology is published online today in European Heart Journal.

26 Aug 2022

Best available chemotherapy for HIV-related Kaposi sarcoma would save lives and be cost-effective in Africa

Although antiretroviral therapy has markedly improved survival in people with AIDS-associated Kaposi sarcoma (a type of cancer caused by a virus), the condition is still a life-threatening problem in low- and middle-income countries.

15 Jul 2022

Biochemist finds new way to protect healthy leukocytes during chemotherapy

A biochemist from RUDN and IBMC has found a way to protect healthy leukocytes during leukemia chemotherapy. Small nitrogen-containing polyamine molecules give the necessary protection.

14 Jul 2022

Novel magnetic therapy complements chemotherapy to enhance breast cancer treatment outcomes

Breast cancer is the leading cause of cancer-associated death for women worldwide. While chemotherapy is the mainstream treatment for breast cancer, more than 50% of women undergoing chemotherapy will experience at least one chemotherapy-related adverse side effect.

3 May 2022

UrFU researchers propose the use of polyoxometallate nanoclusters as chemotherapy drug carrier

Researchers at Ural Federal University have proposed the use of polyoxometallate nanoclusters as a carrier for chemotherapy drug. It will help to deliver medications precisely to the focus of a pathological process, such as a cancerous tumor, without toxic effects on healthy cells.

28 Apr 2022

Novel plug-and-play multi-organ chip can be customized to the patient

Engineered tissues have become a critical component for modeling diseases and testing the efficacy and safety of drugs in a human context.

27 Apr 2022

Researchers develop novel device to “cleanse” the blood of chemotherapeutic drugs

For patients with cancer, the tumor-killing power of chemotherapeutic drugs is a double-edged sword. While many cancer drugs kill tumor cells, they can also harm healthy cells as they travel throughout the bloodstream.

6 Apr 2022

Vitamin C may help to counteract common side effect of the chemotherapy drug

A study conducted in rats suggests that taking vitamin C may help to counteract the muscle atrophy that is a common side effect of the chemotherapy drug doxorubicin.

4 Apr 2022

Lower, more frequent doses of nanomedicines may provide additional benefits for cancer patients

Tiny structures called nanoparticles can be used to carry substances to certain parts of the body-;for example, to deliver a chemotherapy drug to a tumor.

11 Mar 2022

Biomarker could predict pathologic response to chemotherapy among bladder cancer patients

Long-term survival data from the first prospective, randomized biomarker validation trial in patients with muscle-invasive bladder cancer being treated with cisplatin-based chemotherapy before surgery will be reported at the 2022 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (GU ASCO) on February 18, 2022.

15 Feb 2022